RNRasha A. Abdel Noor

Rasha A. Abdel Noor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rasha A. Abdel Noor has a total of 181 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Spectrum of Rheumatic Diseases and Associated Comorbidities among Patients Visiting the Rheumatology Clinic in Taif, Saudi Arabia: A Single-center Experience

    by Rasha Abdel Noor, Waad Kazi, Khalid AlTalhi, Asma Alazwari, Thekra I. Alsalmi, Adel S. Alqahtani, Athar I. Alqurashi, Jehan F. Sarriyah, Sarah Alghalbi, Khaled Alghashmari, et al.

    Background: Autoimmune rheumatic diseases (AIRDs) represent emerging diseases in modern life with a great burden and complications. Objectives: To make a descriptive analysis for a sample of patients came to visit rheumatology clinic in Taif, Saudi Arabia to know the spectrum of rheumatic diseases and associated comorbidities. Materials and Methods: This is a retrospective cross-sectional descriptive analysis done on the patients who came to the rheumatology outpatient clinic for a duration of about 2 years. We retrospectively collect data from the electronic patient files. Demographic data, final diagnosis reached, vitamin D level, and associated comorbidities were reported. Results: Of 1719 patients, 76.96% of patients were females. We diagnosed that 41.53% of patients had AIRDs, 4.81% of patients had gout, 3.19% of patients had fibromyalgia, and 50.49% of patients were referred due to either nonspecific arthralgia or degenerative diseases. The most common AIRDs were rheumatoid arthritis (RA; 50.14%), systemic lupus erythematosus (23.24%), psoriatic arthritis (4.34%), Behçet’s disease (4.06%), and axial spondyloarthritis (2.52%). In most of our cases, vitamin D was found deficient, with a percentage reached 62.61% in AIRDs, 69.5% in gouty patients, 56.4% in fibromyalgia patients, and in most cases with non-AIRDs (61.86%). The most common associated comorbidities in our patients are hypertension, diabetes, hypothyroidism, iron deficiency anemia, dyslipidemia, ischemic heart disease (IHD), and chronic kidney disease (CKD). Conclusion: RA is the most common rheumatic disease noticed in our patients, followed by gouty arthritis and fibromyalgia. Vitamin D deficiency is very common among most patients. Hypertension, diabetes, hypothyroidism, iron deficiency anemia, IHD, CKD, and dyslipidemia are the most common comorbidities among patients with rheumatic diseases.

  • Open Access

    Role of Musculoskeletal Ultrasound in Detecting Subclinical Synovitis in Patients with Systemic Lupus Erythematosus: A Single-center Study on 1650 Joints

    by Heba M. Abdrapo, Abeer A. Shahba, Abdallah A. Elsawy, Rasha A. Abdel Noor

    Background: Musculoskeletal and joint affection represents one of the most common manifestations of systemic lupus erythematosus (SLE). Musculoskeletal ultrasound (MSUS) has proven to be a valuable technique in detection of inflammatory and structural damage. The aim is to detect the role of MSUS in revealing subclinical synovitis in SLE patients without any joint manifestations and to correlate the finding with laboratory parameters. Methodology: We conducted this cross-sectional study on 75 persons: 50 SLE patients and 25 healthy subjects. MSUS with power Doppler of hand and wrist joints (22 joints for each patient and total joints examined for all patients 1650 joints) was done for all subjects. Results: Our study detected synovitis in 33 (44%) subjects, 6 of them (8%) have inactive SLE), 9 (12%) have mild active SLE, 5 (6.6%) have moderate active SLE and 13 (17.3%) are healthy control and as regard number of joints affected synovitis detected in 69 joints (4.18% of all joints examined), 6 (0.36%) joints were in inactive SLE group, 20 (1.2%) joints in mild active SLE group, 15 (0.9%) joints in moderate active SLE group and 28 (1.69%) joints in control group. SLE patients were statistically had more significant synovitis and the number of joints affected were more than normal control, also moderately active lupus patients had more significant synovitis and more affected joints than mildly active and inactively diseased persons. Synovitis correlated positively with erythrocyte sedimentation rate and anti-dsDNA and negatively with C4. Conclusion: MSUS is very helpful in detecting subclinical synovitis in lupus patients without joint manifestation, especially if inflammation markers are elevated.

  • Insight into the Epidemiology of the Adult-onset Systemic Autoimmune Rheumatic Diseases in Egypt: A Descriptive Study of 8690 Patients

    by Doaa H.S. Attia, Eman R. Mohamed, Ahmed Y. Ismaeel, Yossra A. Suliman, Nermeen H.A. Moneim, Rasha A. Abdel Noor

    Background/Objective: Although systemic autoimmune rheumatic diseases (SARDs) seem to be ubiquitous, Africa and the Middle East seem to be a remarkable exception with scarcity of data compared with the developed countries. Furthermore, most of the studies addressed a particular disease. This work aimed to shed light on the relative frequency and epidemiology of the different adult-onset SARDs in Egypt. Methods: This is a retrospective hospital-based study including six university hospitals providing free health care services: Cairo, Alexandria, Tanta, Suez Canal, Beni-Suef and Assiut University Hospitals. All available files for patients attending the outpatient clinics or admitted to the inpatient departments between January 2000 and December 2021 were retrospectively reviewed. Data about the patient’s diagnosis, gender, age at disease onset, year of disease onset and residence were collected. Results: The study included 8690 patients. Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Behçet’s disease (BD) and spondyloarthropathies (SPA) represented the main SARDs in Egypt. They mainly affect young patients below the age of 40 years. RA and SLE mainly affect females; males are mainly affected by axial SPA and BD. There is an increasing incidence of SARDs during the study period. Conclusion: The study revealed the high burden of SARDs in Egypt, helping better allocation of economic resources for the management of diseases of the highest prevalence and those affecting the young reproductive age groups. Increased public and medical staff awareness about SARDs is recommended to help early referral of patients to rheumatologists and, hence, better estimation of their epidemiology.


  • Open Access

    Acceptance, tolerability, and effect of COVID-19 vaccination on disease activity in a cohort of Egyptian systemic lupus erythematosus patients: Real-life experience

    by Mohamed Hassan Abu-Zaid, Hany M. Aly, Abdelhfeez Moshrif, Rasha Abdel Noor, Nehal El-Ghobashy

    Objective: To assess the tolerance and effects of COVID-19 vaccination in Egyptian patients with systemic lupus erythematosus (SLE), such as incident flare risk, based on the patient’s perspective. Methods: SLE patients were included in this multicenter cross-sectional questionnaire-based analysis. Data included demographic and clinical features, prior COVID-19 infection, vaccine acceptability, type of vaccination, disease status before and after vaccination, and related side effects. Results: The total number of patients included was 230. Ages ranged from 18 to 64 years, disease duration from 1 to 15 years, and 92.6% were females. Only 31.7% of the study population were COVID-infected; most (70.7%) were treated at home, while 1.2% needed ICU. In contrast, 53% of our patients were vaccinated, and 47% were not vaccinated, primarily due to fear of side effects or disease flare. After the first dose of vaccination, 44.1% reported vaccine-related side effects, of which fatigue, fever, myalgia, as well as injection site reaction were the prevalent complications. The highest incidence of side effects was in AstraZeneca (78%), while the least was in Sinopharm (29.6%). 16.3% of vaccinated patients were COVID infected after vaccination, and 88.2% were treated at home. Only 14.6% of the vaccinated population experienced a lupus flare, primarily after the first dose, with no significant difference between the type of vaccine and lupus flares. Conclusion: The acceptance of COVID-19 vaccination among our lupus patients was neutral. The observed adverse effects were comparable to those reported by healthy individuals. Post-vaccination lupus flares were infrequent and unrelated to the vaccine type but rather to the pre-vaccination disease activity state. Keywords: Lupus, COVID, Vaccine, Flare

  • Open Access

    Ultrasound abnormalities of the major salivary glands in Egyptian patients with systemic sclerosis

    by Ahmed E. Hafez, AlShaimaa M. Taha, Abdelhfeez Moshrif, Hany M. Aly, Rasha Abdel Noor, Mohamed Mortada, Radwa Elkhouli

    Introduction/objectives: systemic sclerosis (SSc) is an autoimmune disorder with multiple organs destruction. This study aimed to identify the ultrasonographic changes of major salivary glands in Egyptian scleroderma patients and to detect their association to different disease manifestations. Methods: Forty-seven SSc patients and 43 apparent healthy volunteers were enrolled. Demographics, inflammatory markers, and autoimmune status were recorded. Ultrasound evaluation of salivary glands was performed. Salivary gland changes’ associations were statistically examined with SSc susceptibility and disease manifestations. Results: Thirty-one SSc patients exhibited glandular pathology (p < 0.0001), compared to controls. Of these abnormalities, SSc patients showed a total parotid gray scale of 2, total submandibular gray scale of 2, total glandular gray scale of 4, and total glandular Doppler signal of 1 at p < 0.0001, compared to the control group. Patients with SSc and glandular pathology had a higher prevalence of arthritis (p = 0.029) and ESR (p = 0.002) than those with normal glandular ultrasound. Significant associations were reported between gray scale ultrasound (GSUS) of total parotid (odds ratio “OR” = 0.4), total submandibular (OR = 0.36), and total glandular (OR = 0.53) with susceptibility to SSc at p < 0.0001. Total glandular GSUS (p = 0.039) and total submandibular power Doppler (p = 0.044) correlated with the SSc duration. Total parotid GSUS (p = 0.008) and total glandular GSUS (p < 0.0001) correlated with Schirmer’s test. Conclusions: Major salivary glands are affected in SSc. Hence, scanning these glands with ultrasound is an additive tool besides the current practice. Key Points• Major salivary gland changes, observed by ultrasonography, are new findings in Egyptian SSc patients.• Ultrasound changes of major salivary glands are associated with inflammatory markers and clinical manifestations of SSc.• Scleroderma ultrasonography scans of the main salivary glands could be added to the routine work.


  • Metabolic Syndrome in Behçets Disease Patients: Keep an Eye on the Eye

    by Tamer A. Gheita, Suzan S. ElAdle, Eiman Abdel Latif, Yousra H. Abdel-Fattah, Emad El Shebini, Iman I. El-Gazzar, Hanan M. El-Saadany, Nermeen Samy, Reem El-Mallah, Mohamed N. Salem, et al.

    Background: Metabolic syndrome (MetS) is characterized by insulin resistance, high blood pres-sure/sugar, dyslipidemia, and obesity. Whether MetS and its components affect the development of Behçet's Disease (BD) remains unclear. Aims: The aim was to determine the frequency of MetS among BD patients and to study its relationship with disease characteristics. Methods: The study included 1028 adult BD patients recruited from 18 specialized rheumatology centers. 51 healthy matched control were considered. Behçet Disease Current Activity Form (BDCAF) and the BD damage index (BDI) were estimated. Adult Treatment Panel-III criteria were used to define MetS. Results: The mean age of patients was 36.8 ± 10.1 years, M:F 2.7:1 and disease duration 7.01 ± 5.2 years. Their mean BDCAF was 5.1 ± 4.6 and BDI 5.5 ± 2.8. MetS was present in 22.8% of patients and in 5.9% of control (3.9 fold higher-risk). Patients with MetS had a significantly increased age at onset (31.8 ± 9.2 vs. 29 ± 8.5 years) and higher frequency of genital ulcers (96.2% vs. 79.7%), skin involvement (73.1% vs. 50.4%), arthritis (48.3% vs. 29.1%) (p<0.0001) and CNS manifestations (18.8% vs. 13%) (p=0.042) compared to those without it. Eye involvement was significantly increased in those with MetS (82.1% vs. 74.2%) (p=0.003) with increased frequency of posterior uveitis (67.1% vs. 43.5%), retinal vessel occlusion (35.9% vs. 21.3%), retinal vasculitis (41.9% vs. 26.4%) (p<0.0001) and vitritis (37.2% vs. 24%) (p=0.001). BDCAF was significantly lower (3.9 ± 4.3 vs. 5.6 ± 4.6) and BDI higher (7.4 ± 2.7vs5 ± 2.6) (p<0.0001). Conclusion: BD patients with MetS are predisposed to mucocutaneous, musculoskeletal, neuropsychiatric and ocular manifestations with consequently increased damage. The involvement of the deeper structures of the eye should alarm rheumatologists to keep in mind that all patients should have an eye examination, especially those with MetS.


  • Aging and entheses: An ultrasonographic probing of degenerative enthesopathy in a cohort of 147 healthy subjects

    by Abdelhfeez Moshrif, Rasha Abdel Noor, Hany Aly, Mohamed Mortada, Ahmed Hafez

    Aim: To investigate the prevalence and features of degenerative enthesopathic changes in a large cohort of healthy individuals by musculoskeletal ultrasound (MSUS) and their relation to age and other demographic features.Methods: In this cross‐sectional study, 147 healthy subjects (1470 entheses) were examined by MSUS according to the Outcome Measures in Rheumatology guidelines: Achilles tendon, plantar fascia, patellar, and quadriceps insertions of both lower limbs.Results: The mean age (±SD) of the participants was 43.68 (±14.53) years and 57.1% were female. Enthesopathy has been detected in at least 1 area in 113 subjects (76.87%). Thickening (21.6%) and hypoechogenicity (15.3%) were the most frequent inflammatory findings while enthesophyte (10.13%) was the most prevalent structural one. Age and male gender were significantly correlating with inflammatory (rs = .341, P = .001/r = .310, P = .001), structural (rs = .354, P = .001/r = .166, P = .04) and total scores (rs = .406, P = .001/r = .302, P = .001). More inflammatory changes were noticed in the age group 36‐55 years. Body mass index had a positive correlation with inflammatory (rs = .290, P = .001) and total scores (rs = 0.298, P = .001) but not with structural lesions (rs = .154, P = .062).Conclusions: Thickening, hypoechogenicity, cortical irregularities, and enthesophytes are frequent degenerative features of enthesopathy. These findings need to be redefined to be more specific for spondyloarthritides. Enthesopathy should be interpreted with caution in the light of the clinical picture, especially in elderly and obese male patients.


  • Open Access

    Assessment of the Role of Urinary Heparanase in Lupus Nephritis Patients and Its Correlation with Disease Activity

    by Mustafa A. Abou-Alfa, Rasha A. Abdel Noor, Hala M. Nagy, Nesreen A. Kotb

    Assessing the activity of lupus nephritis (LN) with novel biomarkers is a promising noninvasive diagnostic tool for managing systemic lupus erythematosus (SLE). We assessed the ability of urinary heparanase to identify LN and its relation to the disease's activity. This crosssectional study had 90 subjects: 70 patients with SLE and 20 healthy controls. A full medical history, clinical examination, and routine investigations were carried out for the patients and controls. Immunological assays and assessments of the disease's activity with the SLE Disease Activity Index (SLEDAI) and the renal SLEDAI (r-SLEDAI) were carried out for LN groups. Urinary heparanase levels were measured using an enzyme-linked immunosorbent assay for all subjects. Of our patients, 20 had active LN, 17 had nonactive LN, 18 had active lupus without renal involvement, and 15 had nonactive lupus without renal involvement. The level of urinary heparanase was significantly higher in the LN groups than in the non-LN groups and the controls and was significantly higher in those with active LN than in those with nonactive LN. There were significant positive correlations between urinary heparanase and 24-h urinary protein, total SLEDAI, and r-SLEDAI, and significant negative correlations between urinary heparanase and Complements 3 and 4. Urinary heparanase predicted the activity of LN with a sensitivity of 80% and a specificity of 91.43%. Urinary heparanase levels were higher in patients with active LN and correlated with the markers of disease activity, indicating that it can serve as a useful new biomarker for the activity of LN.

  • Open Access

    Clinical and electrophysiological assessment of cranial and peripheral neuropathies in systemic lupus erythematosus patients: Relation to disease activity

    by Heba A. Almokadem, Doaa W. Nada, Rasha A. Abdel Noor, Enas A. El-Zamarany, Elham M. Kassem, Nagat M. El-Gazzar


  • Open Access

    Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt

    by Nevin Hammam, Samar Tharwat, Rawhya R. El Shereef, Ahmed M. Elsaman, Noha M. Khalil, Hanan M. Fathi, Mohamed N. Salem, Hanan M. El-Saadany, Nermeen Samy, Amany S. El-Bahnasawy, et al.

    Objectives The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. Methods The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients. Results 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%). Conclusions The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted.